Merops Switch to
Inhibitors

Peptidase

Family Clan SEARCHES BLAST
MEROPS SUBMISSIONS

Other
information

Structure for peptidase T01.012: proteasome subunit beta5c

Summary Gene structure Alignment Tree Sequences Sequence features Distribution Structure Literature Substrates Pharma

 

TERTIARY STRUCTURE DATA
Comment Resolution PDB PDBe SCOP CATH PDBSum Proteopedia Reference
Bos taurus
20S proteasome complex 2.75 Å 1IRU 1IRU 1IRU 1IRU 1IRU 1IRU Unno et al., 2002
Homo sapiens
cryo-em reveals the conformation of a substrate analogue in the human 20s proteasome core 3.50 Å 5A0Q 5A0Q 5A0Q 5A0Q 5A0Q 5A0Q
26S proteasome; complex with USP14-UbAl 4.35 Å 5GJQ 5GJQ 5GJQ 5GJQ 5GJQ 5GJQ
26S proteasome 3.50 Å 5GJR 5GJR 5GJR 5GJR 5GJR 5GJR
yeast 20s proteasome with human beta5c (1-138) and human beta6 (97- 111; 118-133) 2.80 Å 5L5W 5L5W 5L5W 5L5W 5L5W 5L5W
yeast 20s proteasome with human beta5c (1-138) and human beta6 (97- 111; 118-133) in complex with onx 0914 2.90 Å 5L5X 5L5X 5L5X 5L5X 5L5X 5L5X
yeast 20s proteasome with human beta5c (1-138) and human beta6 (97- 111; 118-133) in complex with carfilzomib 2.70 Å 5L5Y 5L5Y 5L5Y 5L5Y 5L5Y 5L5Y
yeast 20s proteasome with human beta5c (1-138) and human beta6 (97- 111; 118-133) in complex with bortezomib 2.70 Å 5L5Z 5L5Z 5L5Z 5L5Z 5L5Z 5L5Z
yeast 20s proteasome with human beta5c (1-138) and human beta6 (97- 111; 118-133); complex with PR-924 2.70 Å 5L60 5L60 5L60 5L60 5L60 5L60
yeast 20s proteasome with human beta5c (1-138) and human beta6 (99- 132) in complex with epoxyketone inhibitor 14 2.80 Å 5L61 5L61 5L61 5L61 5L61 5L61
yeast 20s proteasome with human beta5c (1-138) and human beta6 (97- 111; 118-133) in complex with epoxyketone inhibitor 16 2.80 Å 5L62 5L62 5L62 5L62 5L62 5L62
yeast 20s proteasome with human beta5c (1-138) and human beta6 (97- 111; 118-133) in complex with epoxyketone inhibitor 17 ***caveat 5l63 04c h 301 has wrong chirality at atom c27 04c k 301 has ***caveat 2 5l63 wrong chirality at atom c27 04c v 301 has wr 2.70 Å 5L63 5L63 5L63 5L63 5L63 5L63
yeast 20s proteasome with human beta5c (1-138) and human beta6 (97- 111; 118-133) in complex with epoxyketone inhibitor 18 2.70 Å 5L64 5L64 5L64 5L64 5L64 5L64
native human 20s proteasome at 1.8 angstrom ***caveat 5le5 6v1 u 47 has wrong chirality at atom c1 1.80 Å 5LE5 5LE5 5LE5 5LE5 5LE5 5LE5
native human 20s proteasome in mg-acetate at 2.2 angstrom ***caveat 5lex 6v1 u 47 has wrong chirality at atom c1 2.20 Å 5LEX 5LEX 5LEX 5LEX 5LEX 5LEX
20s proteasome; complex with oprozomib 1.90 Å 5LEY 5LEY 5LEY 5LEY 5LEY 5LEY
20s proteasome; complex with oprozomib in mg-acetate 2.19 Å 5LEZ 5LEZ 5LEZ 5LEZ 5LEZ 5LEZ
human 20s proteasome complex with epoxomicin at 2.4 angstrom ***caveat 5lf0 6v1 u 47 has wrong chirality at atom c1 iml c 2 has wrong ***caveat 2 5lf0 chirality at atom cb iml d 2 has wrong chirality at atom ca ***caveat 3 5lf0 iml d 2 has wrong chirality 2.41 Å 5LF0 5LF0 5LF0 5LF0 5LF0 5LF0
human 20s proteasome complex with dihydroeponemycin at 2.0 angstrom ***caveat 5lf1 6v1 u 47 has wrong chirality at atom c1 2.00 Å 5LF1 5LF1 5LF1 5LF1 5LF1 5LF1
human 20s proteasome complex with bortezomib at 2.1 angstrom ***caveat 5lf3 6v1 u 47 has wrong chirality at atom c1 2.10 Å 5LF3 5LF3 5LF3 5LF3 5LF3 5LF3
20s proteasome; complex with delanzomib 1.99 Å 5LF4 5LF4 5LF4 5LF4 5LF4 5LF4
human 20s proteasome complex with z-lly-ketoaldehyde at 2.1 angstrom ***caveat 5lf6 6v1 u 47 has wrong chirality at atom c1 2.07 Å 5LF6 5LF6 5LF6 5LF6 5LF6 5LF6
human 20s proteasome complex with ixazomib at 2.0 angstrom ***caveat 5lf7 6v1 u 47 has wrong chirality at atom c1 2.00 Å 5LF7 5LF7 5LF7 5LF7 5LF7 5LF7
the human 26s proteasome at 6.8 ang. ***caveat 5ln3 pro h 311 has wrong chirality at atom ca thr n 752 has wrong ***caveat 2 5ln3 chirality at atom ca 6.80 Å 5LN3 5LN3 5LN3 5LN3 5LN3 5LN3
26s proteasome in complex with oprozomib 3.80 Å 5M32 5M32 5M32 5M32 5M32 5M32
structural basis for dynamic regulation of the human 26s proteasome ***caveat 5t0g entry contains improper peptide linkages. 4.40 Å 5T0G 5T0G 5T0G 5T0G 5T0G 5T0G
structural basis for dynamic regulation of the human 26s proteasome ***caveat 5t0h entry contains improper peptide linkages. 6.80 Å 5T0H 5T0H 5T0H 5T0H 5T0H 5T0H
structural basis for dynamic regulation of the human 26s proteasome ***caveat 5t0i entry contains improper peptide linkages. residue arg k 20 ***caveat 2 5t0i is incorrectly modeled. 8.00 Å 5T0I 5T0I 5T0I 5T0I 5T0I 5T0I
structural basis for dynamic regulation of the human 26s proteasome ***caveat 5t0j entry contains improper peptide linkages. 8.00 Å 5T0J 5T0J 5T0J 5T0J 5T0J 5T0J
nucleotide-driven triple-state remodeling of the aaa-atpase channel inthe activated human 26s proteasome 3.50 Å 5VFO 5VFO 5VFO 5VFO 5VFO 5VFO
nucleotide-driven triple-state remodeling of the aaa-atpase channel inthe activated human 26s proteasome 4.90 Å 5VFR 5VFR 5VFR 5VFR 5VFR 5VFR
nucleotide-driven triple-state remodeling of the aaa-atpase channel inthe activated human 26s proteasome 7.00 Å 5VFT 5VFT 5VFT 5VFT 5VFT 5VFT
endogeneous native human 20s proteasome 3.50 Å 6R70 6R70 6R70 6R70 6R70 6R70
Mus musculus
20S proteasome; complex with PR-957 2.90 Å 3UNB 3UNB 3UNB 3UNB 3UNB 3UNB Huber et al., 2012
20S proteasome 3.20 Å 3UNE 3UNE 3UNE 3UNE 3UNE 3UNE Huber et al., 2012
mature  peptidase 2.90 Å 3UNF 3UNF 3UNF 3UNF 3UNF 3UNF Huber et al., 2012
20S immunoproteasome 3.20 Å 3UNH 3UNH 3UNH 3UNH 3UNH 3UNH Huber et al., 2012
yeast 20s proteasome with mouse beta5i (1-138) and mouse beta6 (97- 111; 118-133) in complex with carfilzomib 2.90 Å 5L65 5L65 5L65 5L65 5L65 5L65
yeast 20s proteasome with mouse beta5i (1-138) and mouse beta6 (97- 111; 118-133) in complex with bortezomib 2.80 Å 5L66 5L66 5L66 5L66 5L66 5L66
yeast 20s proteasome with mouse beta5i (1-138) and mouse beta6 (97- 111; 118-133); complex with PR-924 2.60 Å 5L67 5L67 5L67 5L67 5L67 5L67
yeast 20s proteasome with mouse beta5i (1-138) and mouse beta6 (97- 111; 118-133) in complex with epoxyketone inhibitor 14 2.80 Å 5L68 5L68 5L68 5L68 5L68 5L68
yeast 20s proteasome with mouse beta5i (1-138) and mouse beta6 (97- 111; 118-133) in complex with epoxyketone inhibitor 16 2.70 Å 5L69 5L69 5L69 5L69 5L69 5L69
yeast 20s proteasome with mouse beta5i (1-138) and mouse beta6 (97- 111; 118-133) in complex with epoxyketone inhibitor 17 2.80 Å 5L6A 5L6A 5L6A 5L6A 5L6A 5L6A
yeast 20s proteasome with mouse beta5i (1-138) and mouse beta6 (97- 111; 118-133) in complex with onx 0914 2.60 Å 5L6B 5L6B 5L6B 5L6B 5L6B 5L6B
yeast 20s proteasome with mouse beta5i (1-138) and mouse beta6 (97- 111; 118-133) in complex with epoxyketone inhibitor 18 2.60 Å 5L6C 5L6C 5L6C 5L6C 5L6C 5L6C
Rattus norvegicus
ground state 26s proteasome (gs2) 12.30 Å 6EPC 6EPC 6EPC 6EPC 6EPC 6EPC
substrate processing state 26s proteasome (sps1) ***caveat 6epd pro 2 231 has wrong chirality at atom ca 15.40 Å 6EPD 6EPD 6EPD 6EPD 6EPD 6EPD
substrate processing state 26s proteasome (sps2) 12.80 Å 6EPE 6EPE 6EPE 6EPE 6EPE 6EPE
ground state 26s proteasome (gs1) 11.80 Å 6EPF 6EPF 6EPF 6EPF 6EPF 6EPF
Saccharomyces cerevisiae
20S proteasome in complex with activator PA26 (Trypanosoma brucei) 3.20 Å 1FNT 1FNT 1FNT 1FNT 1FNT 1FNT Whitby et al., 2000
complete proteasome 2.40 Å 1G0U 1G0U 1G0U 1G0U 1G0U 1G0U Groll et al., 2000
complex with epoxomicin 2.25 Å 1G65 1G65 1G65 1G65 1G65 1G65 Groll et al., 2000
proteasome complex bound to TMC-95A inhibitor 3.00 Å 1JD2 1JD2 1JD2 1JD2 1JD2 1JD2 Groll et al., 2001
20S proteasome 2.40 Å 1RYP 1RYP 1RYP 1RYP 1RYP 1RYP Groll et al., 1997
20S proteasome; complex with the proteasome activator PA26 from Trypanosoma brucei 3.22 Å 1Z7Q 1Z7Q 1Z7Q 1Z7Q 1Z7Q 1Z7Q Forster et al., 2005
20S proteasome;complex with bortezomib 2.80 Å 2F16 2F16 2F16 2F16 2F16 2F16 Groll et al., 2006
20S proteasome; complex with salinosporamide A 2.80 Å 2FAK 2FAK 2FAK 2FAK 2FAK 2FAK Groll et al., 2006
20S proteasome; complex with homobelactosin C 3.00 Å 2FNY 2FNY 2FNY 2FNY 2FNY 2FNY Groll et al., 2006
20S proteasome; complex with TMC-95 based biphenyl-ether macrocycle 2.81 Å 2GPL 2GPL 2GPL 2GPL 2GPL 2GPL Groll et al., 2006
20S proteasome; complex with syringolin A 2.90 Å 2ZCY 2ZCY 2ZCY 2ZCY 2ZCY 2ZCY Groll et al., 2008
20S proteasome; complex with glidobactin A 2.70 Å 3BDM 3BDM 3BDM 3BDM 3BDM 3BDM Groll et al., 2008
20S proteasome; complex with fellutamide B 2.60 Å 3D29 3D29 3D29 3D29 3D29 3D29 Hines et al., 2008
20s proteasome; complex with the epimer form of spirolactacystin 2.81 Å 3DY3 3DY3 3DY3 3DY3 3DY3 3DY3 Groll et al., 2008
20s proteasome; complex with spirolactacystin 2.80 Å 3DY4 3DY4 3DY4 3DY4 3DY4 3DY4 Groll et al., 2008
20s proteasome; complex with homobelactosin c 3.00 Å 3E47 3E47 3E47 3E47 3E47 3E47 Groll et al., 2006
20s proteasome; complex with syringolin b 2.70 Å 3GPJ 3GPJ 3GPJ 3GPJ 3GPJ 3GPJ Clerc et al., 2009
20S proteasome; complex with salinosporamide derivative 2.41 Å 3GPT 3GPT 3GPT 3GPT 3GPT 3GPT Groll et al., 2009
20S proteasome; complex with salinosporamide derivative 2.50 Å 3GPW 3GPW 3GPW 3GPW 3GPW 3GPW Groll et al., 2009
20S proteasome; complex with hyroxylated salinosporamide 2.50 Å 3HYE 3HYE 3HYE 3HYE 3HYE 3HYE Groll et al., 2009
20S proteasome; complex with bortezomib 2.68 Å 3MG0 3MG0 3MG0 3MG0 3MG0 3MG0 Blackburn et al., 2010
20S proteasome; complex with compound 1 3.11 Å 3MG4 3MG4 3MG4 3MG4 3MG4 3MG4 Blackburn et al., 2010
20S proteasome; complex with compound 6 2.60 Å 3MG6 3MG6 3MG6 3MG6 3MG6 3MG6 Blackburn et al., 2010
20S open-gate proteasome; complex with compound 6 2.78 Å 3MG7 3MG7 3MG7 3MG7 3MG7 3MG7 Blackburn et al., 2010
20S open-gate proteasome; complex with compound 16 2.59 Å 3MG8 3MG8 3MG8 3MG8 3MG8 3MG8 Blackburn et al., 2010
20S proteasome; complex with ligand 2a 2.40 Å 3NZJ 3NZJ 3NZJ 3NZJ 3NZJ 3NZJ Groll et al., 2010
20S proteasome; complex with ligand 2b 2.50 Å 3NZW 3NZW 3NZW 3NZW 3NZW 3NZW Groll et al., 2010
20S proteasome; complex with ligand 2c 2.70 Å 3NZX 3NZX 3NZX 3NZX 3NZX 3NZX Groll et al., 2010
20S open-gate proteasome; complex with compound 24 2.60 Å 3OEU 3OEU 3OEU 3OEU 3OEU 3OEU Blackburn et al., 2010
20S open-gate proteasome; complex with compound 25 2.85 Å 3OEV 3OEV 3OEV 3OEV 3OEV 3OEV Blackburn et al., 2010
20S proteasome; complex with alpha-keto-aldehyde 2.70 Å 3OKJ 3OKJ 3OKJ 3OKJ 3OKJ 3OKJ Grawert et al., 2011
20S open-gate proteasome; complex with compound 20 2.65 Å 3SDI 3SDI 3SDI 3SDI 3SDI 3SDI Blackburn et al., 2010
20S open-gate proteasome; complex with compound 34 2.70 Å 3SDK 3SDK 3SDK 3SDK 3SDK 3SDK Blackburn et al., 2010
20S proteasome; complex with hydroxyurea derivative HU10 2.80 Å 3SHJ 3SHJ 3SHJ 3SHJ 3SHJ 3SHJ Gallastegui et al., 2012
20S proteasome; complex with homobelactosin C 2.70 Å 3TDD 3TDD 3TDD 3TDD 3TDD 3TDD Korotkov et al., 2011
20S open-gate proteasome; complex with PR-957 (morpholine) 3.40 Å 3UN4 3UN4 3UN4 3UN4 3UN4 3UN4 Huber et al., 2012
20S proteasome; complex with PR-957 (epoxide) 2.70 Å 3UN8 3UN8 3UN8 3UN8 3UN8 3UN8 Huber et al., 2012
26S proteasome 3.15 Å 3WXR 3WXR 3WXR 3WXR 3WXR 3WXR Yashiroda et al., 2015
26S proteasome 7.70 Å 4CR2 4CR2 4CR2 4CR2 4CR2 4CR2 Unverdorben et al., 2014
mature  peptidase 9.30 Å 4CR3 4CR3 4CR3 4CR3 4CR3 4CR3 Unverdorben et al., 2014
26S proteasome 8.80 Å 4CR4 4CR4 4CR4 4CR4 4CR4 4CR4 Unverdorben et al., 2014
20S proteasome; complex with K-7174 2.51 Å 4EU2 4EU2 4EU2 4EU2 4EU2 4EU2 Kikuchi et al., 2013
20S proteasome; complex with cepafungin I 2.80 Å 4FZC 4FZC 4FZC 4FZC 4FZC 4FZC Stein et al., 2012
20S proteasome; complex with glidobactin 3.00 Å 4FZG 4FZG 4FZG 4FZG 4FZG 4FZG Stein et al., 2012
20S proteasome; complex with Syringolin-Glidobactin chimera 2.49 Å 4G4S 4G4S 4G4S 4G4S 4G4S 4G4S Stadtmueller et al., 2012
20S proteasome; complex with Syringolin-Glidobactin chimera 2.80 Å 4GK7 4GK7 4GK7 4GK7 4GK7 4GK7 Archer et al., 2012
20S proteasome; complex with vinylketone carmaphycin analogue VNK1 2.80 Å 4HNP 4HNP 4HNP 4HNP 4HNP 4HNP Trivella et al., 2014
20S proteasome; complex with epoxyketone carmaphycin analogue 3 2.80 Å 4HRC 4HRC 4HRC 4HRC 4HRC 4HRC Trivella et al., 2014
20S proteasome; complex with carmaphycin A 2.80 Å 4HRD 4HRD 4HRD 4HRD 4HRD 4HRD Trivella et al., 2014
20S proteasome; complex with vinyl sulfone LU102 2.70 Å 4INR 4INR 4INR 4INR 4INR 4INR Geurink et al., 2013
20S proteasome; complex with vinyl sulfone LU122 2.90 Å 4INT 4INT 4INT 4INT 4INT 4INT Geurink et al., 2013
20S proteasome; complex with vinyl sulfone LU112 3.10 Å 4INU 4INU 4INU 4INU 4INU 4INU Geurink et al., 2013
20S proteasome; complex with belactosin derivative 3E 2.80 Å 4J70 4J70 4J70 4J70 4J70 4J70 Kawamura et al., 2013
20S proteasome; complex with dimerized linear mimetic of TMC-95A 2.80 Å 4JSQ 4JSQ 4JSQ 4JSQ 4JSQ 4JSQ Desvergne et al., 2013
20S proteasome; complex with dimerized linear mimetic of TMC-95A 2.90 Å 4JSU 4JSU 4JSU 4JSU 4JSU 4JSU Desvergne et al., 2013
20S proteasome; complex with dimerized linear mimetic of TMC-95A 3.10 Å 4JT0 4JT0 4JT0 4JT0 4JT0 4JT0 Desvergne et al., 2013
20S proteasome; complex with vibralactone 2.70 Å 4LQI 4LQI 4LQI 4LQI 4LQI 4LQI List et al., 2014
20S proteasome; complex with enone carmaphycin analogue 6 2.50 Å 4LTC 4LTC 4LTC 4LTC 4LTC 4LTC Trivella et al., 2014
20S proteasome; complex with MG132 2.50 Å 4NNN 4NNN 4NNN 4NNN 4NNN 4NNN Stein et al., 2014
20S proteasome; complex with Z-Leu-Leu-Leu-ketoaldehyde 2.60 Å 4NNW 4NNW 4NNW 4NNW 4NNW 4NNW Stein et al., 2014
20S proteasome; complex with Z-Leu-Leu-Leu-B(OH)2 2.50 Å 4NO1 4NO1 4NO1 4NO1 4NO1 4NO1 Stein et al., 2014
20S proteasome; complex with Z-Leu-Leu-Leu-vinylsulfone 3.00 Å 4NO6 4NO6 4NO6 4NO6 4NO6 4NO6 Stein et al., 2014
20S proteasome; complex with Z-Leu-Leu-Leu-ketoamide 2.70 Å 4NO8 4NO8 4NO8 4NO8 4NO8 4NO8 Stein et al., 2014
20S proteasome; complex with Z-Leu-Leu-Leu-epoxyketone 2.90 Å 4NO9 4NO9 4NO9 4NO9 4NO9 4NO9 Stein et al., 2014
20S proteasome; complex with kendomycin 2.60 Å 4Q1S 4Q1S 4Q1S 4Q1S 4Q1S 4Q1S Beck et al., 2014
20S proteasome; complex with Boc-Ala-Ala-Ala-CHO 3.00 Å 4QBY 4QBY 4QBY 4QBY 4QBY 4QBY Arciniega et al., 2014
20S proteasome; complex with epoxyketone inhibitor 8 2.40 Å 4QLQ 4QLQ 4QLQ 4QLQ 4QLQ 4QLQ de Bruin et al., 2014
20S proteasome; complex with epoxyketone inhibitor 11 2.80 Å 4QLS 4QLS 4QLS 4QLS 4QLS 4QLS de Bruin et al., 2014
20S proteasome; complex with tripeptidic epoxyketone inhibitor 2 2.80 Å 4QLT 4QLT 4QLT 4QLT 4QLT 4QLT de Bruin et al., 2014
20S proteasome; complex with tripeptidic epoxyketone inhibitor 9 2.80 Å 4QLU 4QLU 4QLU 4QLU 4QLU 4QLU de Bruin et al., 2014
20S proteasome; complex with tripeptidic epoxyketone inhibitor 17 2.90 Å 4QLV 4QLV 4QLV 4QLV 4QLV 4QLV de Bruin et al., 2014
20S proteasome; Ala49Thr mutant 3.00 Å 4QUX 4QUX 4QUX 4QUX 4QUX 4QUX Huber et al., 2015
20S proteasome; Ala49Ser mutant 2.80 Å 4QUY 4QUY 4QUY 4QUY 4QUY 4QUY Huber et al., 2015
20S proteasome; Ala49Thr, Ala50Val mutant 3.10 Å 4QV0 4QV0 4QV0 4QV0 4QV0 4QV0 Huber et al., 2015
20S proteasome; Met45Ala mutant 2.50 Å 4QV1 4QV1 4QV1 4QV1 4QV1 4QV1 Huber et al., 2015
20S proteasome; Met45Val mutant 3.00 Å 4QV3 4QV3 4QV3 4QV3 4QV3 4QV3 Huber et al., 2015
20S proteasome beta5 Met45Thr mutant 2.70 Å 4QV4 4QV4 4QV4 4QV4 4QV4 4QV4 Huber et al., 2015
20S proteasome beta5 Met45Ile mutant 2.70 Å 4QV5 4QV5 4QV5 4QV5 4QV5 4QV5 Huber et al., 2015
20S proteasome; Ala49Val mutant 2.80 Å 4QV6 4QV6 4QV6 4QV6 4QV6 4QV6 Huber et al., 2015
20S proteasome; Ala50Val mutant 2.60 Å 4QV7 4QV7 4QV7 4QV7 4QV7 4QV7 Huber et al., 2015
20S proteasome; Cys52Phe mutant 2.90 Å 4QV8 4QV8 4QV8 4QV8 4QV8 4QV8 Huber et al., 2015
20S proteasome; Cys63Phe mutant 2.60 Å 4QV9 4QV9 4QV9 4QV9 4QV9 4QV9 Huber et al., 2015
20S proteasome; complex with bortezomib 2.80 Å 4QVL 4QVL 4QVL 4QVL 4QVL 4QVL Huber et al., 2015
20S proteasome beta5 Met45Ala mutant; complex with bortezomib 2.80 Å 4QVM 4QVM 4QVM 4QVM 4QVM 4QVM Huber et al., 2015
20S proteasome beta5 Met45Val mutant; complex with bortezomib 2.90 Å 4QVN 4QVN 4QVN 4QVN 4QVN 4QVN Huber et al., 2015
20S proteasome beta5 Met45Thr mutant; complex with bortezomib 2.30 Å 4QVP 4QVP 4QVP 4QVP 4QVP 4QVP Huber et al., 2015
20S proteasome beta5 Met45Ile mutant; complex with bortezomib 2.60 Å 4QVQ 4QVQ 4QVQ 4QVQ 4QVQ 4QVQ Huber et al., 2015
20S proteasome beta5 Ala49Val mutant; complex with bortezomib 2.80 Å 4QVV 4QVV 4QVV 4QVV 4QVV 4QVV Huber et al., 2015
20S proteasome beta5 Ala49Ser mutant; complex with bortezomib 3.00 Å 4QVW 4QVW 4QVW 4QVW 4QVW 4QVW Huber et al., 2015
20S proteasome beta5 Ala49Thr mutant; complex with bortezomib 2.51 Å 4QVY 4QVY 4QVY 4QVY 4QVY 4QVY Huber et al., 2015
20S proteasome beta5 Ala49Thr,Ala50Val mutant; complex with bortezomib 2.90 Å 4QW0 4QW0 4QW0 4QW0 4QW0 4QW0 Huber et al., 2015
20S proteasome beta5 Ala50Val mutant; complex with bortezomib 2.90 Å 4QW1 4QW1 4QW1 4QW1 4QW1 4QW1 Huber et al., 2015
20S proteasome beta5 Cys63Phe mutant; complex with bortezomib 2.90 Å 4QW3 4QW3 4QW3 4QW3 4QW3 4QW3 Huber et al., 2015
20S proteasome; complex with carfilzomib 2.80 Å 4QW4 4QW4 4QW4 4QW4 4QW4 4QW4 Huber et al., 2015
20S proteasome beta5 Met45Ala mutant; complex with carfilzomib 3.00 Å 4QW5 4QW5 4QW5 4QW5 4QW5 4QW5 Huber et al., 2015
20S proteasome beta5 Met45Val mutant; complex with carfilzomib 2.90 Å 4QW6 4QW6 4QW6 4QW6 4QW6 4QW6 Huber et al., 2015
20S proteasome beta5 Met45Thr mutant; complex with carfilzomib 2.70 Å 4QW7 4QW7 4QW7 4QW7 4QW7 4QW7 Huber et al., 2015
20S proteasome beta5 Met45Ile mutant; complex with carfilzomib 3.00 Å 4QWF 4QWF 4QWF 4QWF 4QWF 4QWF Huber et al., 2015
20S proteasome beta5 Ala49Val mutant; complex with carfilzomib 2.60 Å 4QWG 4QWG 4QWG 4QWG 4QWG 4QWG Huber et al., 2015
20S proteasome beta5 Ala49Ser mutant; complex with carfilzomib 2.60 Å 4QWI 4QWI 4QWI 4QWI 4QWI 4QWI Huber et al., 2015
20S proteasome beta5 Ala49Thr mutant; complex with carfilzomib 2.90 Å 4QWJ 4QWJ 4QWJ 4QWJ 4QWJ 4QWJ Huber et al., 2015
20S proteasome beta5 Ala49Thr, Ala50Val mutant; complex with carfilzomib 2.80 Å 4QWK 4QWK 4QWK 4QWK 4QWK 4QWK Huber et al., 2015
20S proteasome beta5 Ala50Val mutant; complex with carfilzomib 2.60 Å 4QWL 4QWL 4QWL 4QWL 4QWL 4QWL Huber et al., 2015
20S proteasome beta5 Cys52Phe mutant; complex with carfilzomib 2.90 Å 4QWR 4QWR 4QWR 4QWR 4QWR 4QWR Huber et al., 2015
20S proteasome beta5 Cys63Phe mutant; complex with carfilzomib 3.00 Å 4QWS 4QWS 4QWS 4QWS 4QWS 4QWS Huber et al., 2015
20S proteasome beta5 Cys52Phe mutant; complex with bortezomib 3.00 Å 4QWU 4QWU 4QWU 4QWU 4QWU 4QWU Huber et al., 2015
20S proteasome; complex with epoxyketone inhibitor ONX 0914 2.90 Å 4QWX 4QWX 4QWX 4QWX 4QWX 4QWX Huber et al., 2015
20S proteasome beta 5 Met45Ala mutant; complex with epoxyketone inhibitor ONX 0914 2.80 Å 4QXJ 4QXJ 4QXJ 4QXJ 4QXJ 4QXJ Huber et al., 2015
complete proteasome; complex with epoxyketone inhibitor ONX 0914 3.00 Å 4QZ0 4QZ0 4QZ0 4QZ0 4QZ0 4QZ0 Huber et al., 2015
20S proteasome beta 5 Met45Thr mutant; complex with epoxyketone inhibitor ONX 0914 3.00 Å 4QZ1 4QZ1 4QZ1 4QZ1 4QZ1 4QZ1 Huber et al., 2015
20S proteasome beta 5 Met45Ile mutant; complex with epoxyketone inhibitor ONX 0914 2.70 Å 4QZ2 4QZ2 4QZ2 4QZ2 4QZ2 4QZ2 Huber et al., 2015
20S proteasome beta 5 Ala49Val mutant; complex with epoxyketone inhibitor ONX 0914 2.80 Å 4QZ3 4QZ3 4QZ3 4QZ3 4QZ3 4QZ3 Huber et al., 2015
20S proteasome beta 5 Ala49Ser mutant; complex with epoxyketone inhibitor ONX 0914 3.00 Å 4QZ4 4QZ4 4QZ4 4QZ4 4QZ4 4QZ4 Huber et al., 2015
20S proteasome beta 5 Ala49Thr mutant; complex with epoxyketone inhibitor ONX 0914 2.80 Å 4QZ5 4QZ5 4QZ5 4QZ5 4QZ5 4QZ5 Huber et al., 2015
20S proteasome beta 5 Ala49Thr, Ala50Val mutant; complex with epoxyketone inhibitor ONX 0914 2.90 Å 4QZ6 4QZ6 4QZ6 4QZ6 4QZ6 4QZ6 Huber et al., 2015
20S proteasome beta 5 Ala50Val mutant; complex with epoxyketone inhibitor ONX 0914 2.80 Å 4QZ7 4QZ7 4QZ7 4QZ7 4QZ7 4QZ7 Huber et al., 2015
20S proteasome beta 5 Cys52Phe mutant; complex with epoxyketone inhibitor ONX 0914 3.00 Å 4QZW 4QZW 4QZW 4QZW 4QZW 4QZW Huber et al., 2015
complete proteasome; complex with epoxyketone inhibitor ONX 0914 2.60 Å 4QZX 4QZX 4QZX 4QZX 4QZX 4QZX Huber et al., 2015
20S proteasome; complex with omuralide 2.90 Å 4QZZ 4QZZ 4QZZ 4QZZ 4QZZ 4QZZ Huber et al., 2015
20S proteasome beta 5 Cys52Phe mutant; complex with omuralide 2.80 Å 4R00 4R00 4R00 4R00 4R00 4R00 Huber et al., 2015
20S proteasome; complex with BSC4999 2.50 Å 4R02 4R02 4R02 4R02 4R02 4R02 Voss et al., 2014
20S proteasome; ligand induced aziridine-formation in beta5 2.10 Å 4R17 4R17 4R17 4R17 4R17 4R17 Dubiella et al., 2014
20S proteasome; ligand induced Lys33-Thr1 cross-linking in beta5 2.40 Å 4R18 4R18 4R18 4R18 4R18 4R18 Dubiella et al., 2014
20S proteasome; complex with alkaloid indolo-phakellin 2.50 Å 4RUR 4RUR 4RUR 4RUR 4RUR 4RUR Beck et al., 2015
mature  peptidase 3.00 Å 4V7O 4V7O 4V7O 4V7O 4V7O 4V7O
20S proteasome; complex with PR-VI modulator 2.70 Å 4X6Z 4X6Z 4X6Z 4X6Z 4X6Z 4X6Z
20S proteasome; complex with Ac-Pro-Ala-Asp-EP 2.90 Å 4Y69 4Y69 4Y69 4Y69 4Y69 4Y69 Huber et al., 2015
20S proteasome beta2 His114Asp mutant; complex with Ac-Pro-Ala-Asp-EP 2.60 Å 4Y6A 4Y6A 4Y6A 4Y6A 4Y6A 4Y6A Huber et al., 2015
20S proteasome; complex with Ac-Pro-Ala-Glu-EP 2.80 Å 4Y6V 4Y6V 4Y6V 4Y6V 4Y6V 4Y6V Huber et al., 2015
20S proteasome; complex with Ac-Pro-Ala-Leu-EP 2.70 Å 4Y6Z 4Y6Z 4Y6Z 4Y6Z 4Y6Z 4Y6Z Huber et al., 2015
20S proteasome; complex with Ac-Leu-Ala-Val-EP 2.40 Å 4Y70 4Y70 4Y70 4Y70 4Y70 4Y70 Huber et al., 2015
20S proteasome; complex with Ac-Leu-Ala-Leu-EP 2.70 Å 4Y74 4Y74 4Y74 4Y74 4Y74 4Y74 Huber et al., 2015
20S proteasome; complex with Ac-Pro-Ala-Phe-EP 2.80 Å 4Y75 4Y75 4Y75 4Y75 4Y75 4Y75 Huber et al., 2015
20S proteasome; complex with Ac-Leu-Ala-Phe-EP 2.50 Å 4Y77 4Y77 4Y77 4Y77 4Y77 4Y77 Huber et al., 2015
20S proteasome; complex with Ac-Leu-Ala-Asp-EP 2.80 Å 4Y78 4Y78 4Y78 4Y78 4Y78 4Y78 Huber et al., 2015
20S proteasome; complex with Ac-Leu-Ala-Glu-EP 2.50 Å 4Y7W 4Y7W 4Y7W 4Y7W 4Y7W 4Y7W Huber et al., 2015
complete proteasome; complex with Ac-PAA-ep 2.60 Å 4Y7X 4Y7X 4Y7X 4Y7X 4Y7X 4Y7X Huber et al., 2015
20S proteasome; complex with Ac-Leu-Ala-Ala-EP 2.40 Å 4Y7Y 4Y7Y 4Y7Y 4Y7Y 4Y7Y 4Y7Y Huber et al., 2015
20S proteasome; complex with Ac-Leu-Ala-Ile-EP 2.50 Å 4Y80 4Y80 4Y80 4Y80 4Y80 4Y80 Huber et al., 2015
20S proteasome; complex with Ac-Pro-Ala-Tyr-EP 2.80 Å 4Y81 4Y81 4Y81 4Y81 4Y81 4Y81 Huber et al., 2015
20S proteasome; complex with Ac-Leu-Ala-Tyr-EP 2.80 Å 4Y82 4Y82 4Y82 4Y82 4Y82 4Y82 Huber et al., 2015
20S proteasome; complex with N3-Ala(4,4-F2P)-Asn-Leu-Leu-EP 2.70 Å 4Y84 4Y84 4Y84 4Y84 4Y84 4Y84 Huber et al., 2015
20S proteasome; complex with N3-Ala-Pro-Asn-Leu-Leu-EP 2.60 Å 4Y8G 4Y8G 4Y8G 4Y8G 4Y8G 4Y8G Huber et al., 2015
20S proteasome; complex with N3-Ala-Pro-Ala-Leu-EP 2.50 Å 4Y8H 4Y8H 4Y8H 4Y8H 4Y8H 4Y8H Huber et al., 2015
20S proteasome; complex with Ac-Pro-Leu-Leu-EP 2.60 Å 4Y8I 4Y8I 4Y8I 4Y8I 4Y8I 4Y8I Huber et al., 2015
20S proteasome; complex with Ac-Leu-Leu-Leu-EP 2.70 Å 4Y8J 4Y8J 4Y8J 4Y8J 4Y8J 4Y8J Huber et al., 2015
20S proteasome; complex with H-Ala-Pro-Leu-Leu-EP 2.60 Å 4Y8K 4Y8K 4Y8K 4Y8K 4Y8K 4Y8K Huber et al., 2015
20S proteasome; complex with Ac-Ala-Pro-Leu-Leu-EP 2.40 Å 4Y8L 4Y8L 4Y8L 4Y8L 4Y8L 4Y8L Huber et al., 2015
20S proteasome beta7-delta7 C-terminal mutant 2.80 Å 4Y8M 4Y8M 4Y8M 4Y8M 4Y8M 4Y8M Huber et al., 2015
20S proteasome beta7-delta7 C-terminal mutant; complex with Ac-Pro-Ala-Glu-EP 2.60 Å 4Y8N 4Y8N 4Y8N 4Y8N 4Y8N 4Y8N Huber et al., 2015
20S proteasome beta 7-delta 7 C-terminal mutant; complex with Ac-Pro-Ala-Phe-EP 2.70 Å 4Y8O 4Y8O 4Y8O 4Y8O 4Y8O 4Y8O Huber et al., 2015
20S proteasome beta 7-delta 7 C-terminal mutant; complex with Ac-Pro-Ala-Leu-EP 2.80 Å 4Y8P 4Y8P 4Y8P 4Y8P 4Y8P 4Y8P Huber et al., 2015
20S proteasome beta 7-delta 7 C-terminal mutant; complex with Ac-Pro-Ala-Tyr-EP 2.60 Å 4Y8Q 4Y8Q 4Y8Q 4Y8Q 4Y8Q 4Y8Q Huber et al., 2015
20S proteasome beta 2 His116Asp mutant 2.70 Å 4Y8R 4Y8R 4Y8R 4Y8R 4Y8R 4Y8R Huber et al., 2015
20S proteasome beta 2 His116Asp mutant; complex with Ac-Leu-Ala-Glu-EP 2.70 Å 4Y8S 4Y8S 4Y8S 4Y8S 4Y8S 4Y8S Huber et al., 2015
20S proteasome beta 2 His116Asp mutant; complex with Ac-Pro-Ala-Glu-EP 2.70 Å 4Y8T 4Y8T 4Y8T 4Y8T 4Y8T 4Y8T Huber et al., 2015
20S proteasome beta 2 His116Asp mutant; complex with Ac-Pro-Ala-Asp-EP 2.90 Å 4Y8U 4Y8U 4Y8U 4Y8U 4Y8U 4Y8U Huber et al., 2015
20S proteasome beta 2 His116Glu mutant 2.80 Å 4Y9Y 4Y9Y 4Y9Y 4Y9Y 4Y9Y 4Y9Y Huber et al., 2015
20S proteasome beta 2 His116Glu mutant; complex with Ac-Leu-Ala-Glu-EP 2.80 Å 4Y9Z 4Y9Z 4Y9Z 4Y9Z 4Y9Z 4Y9Z Huber et al., 2015
20S proteasome beta 2 His116Glu mutant; complex with Ac-Pro-Ala-Glu-EP 2.80 Å 4YA0 4YA0 4YA0 4YA0 4YA0 4YA0 Huber et al., 2015
20S proteasome beta 2 His116Asn mutant 2.90 Å 4YA1 4YA1 4YA1 4YA1 4YA1 4YA1 Huber et al., 2015
20S proteasome beta 2 His116Asn mutant; complex with Ac-Leu-Ala-Glu-EP 2.70 Å 4YA2 4YA2 4YA2 4YA2 4YA2 4YA2 Huber et al., 2015
20S proteasome beta 2 His116Asn mutant; complex with Ac-Pro-Ala-Glu-EP 2.70 Å 4YA3 4YA3 4YA3 4YA3 4YA3 4YA3 Huber et al., 2015
20S proteasome beta 2 His114Asp mutant 2.90 Å 4YA4 4YA4 4YA4 4YA4 4YA4 4YA4 Huber et al., 2015
20S proteasome beta 2 His114Asp mutant; complex with Ac-Pro-Ala-Glu-EP 2.50 Å 4YA5 4YA5 4YA5 4YA5 4YA5 4YA5 Huber et al., 2015
20S proteasome beta 2 His114Asp mutant; complex with Ac-Leu-Ala-Glu-EP 2.70 Å 4YA7 4YA7 4YA7 4YA7 4YA7 4YA7 Huber et al., 2015
20S proteasome beta 2 His114Asp mutant; complex with AC-Leu-Ala-Asp-EP 2.70 Å 4YA9 4YA9 4YA9 4YA9 4YA9 4YA9 Huber et al., 2015
20S proteasome; complex with belactosin C derivative 3 3.00 Å 4Z1L 4Z1L 4Z1L 4Z1L 4Z1L 4Z1L Groll et al., 2015
mature  peptidase 9.50 Å 5A5B 5A5B 5A5B 5A5B 5A5B 5A5B Aufderheide et al., 2015
20S proteasome; complex with macyranone A 2.80 Å 5AHJ 5AHJ 5AHJ 5AHJ 5AHJ 5AHJ Keller et al., 2015
20S proteasome; complex with beta1/beta2 nonspecifici sulfonamide ligand 2.60 Å 5BOU 5BOU 5BOU 5BOU 5BOU 5BOU Beck et al., 2015
yeast 20s proteasome beta2-g170a mutant 2.80 Å 5BXL 5BXL 5BXL 5BXL 5BXL 5BXL
yeast 20s proteasome beta2-g170a mutant in complex with bortezomib 2.80 Å 5BXN 5BXN 5BXN 5BXN 5BXN 5BXN
20S proteasome beta5 Gly48Cys mutant 2.80 Å 5CGF 5CGF 5CGF 5CGF 5CGF 5CGF Dubiella et al., 2015
20S proteasome beta5 Gly48Cys mutant; complex with alpha-chloroacetamide 1 2.90 Å 5CGG 5CGG 5CGG 5CGG 5CGG 5CGG Dubiella et al., 2015
20S proteasome beta5 Gly48Cys mutant; complex with alpha-chloroacetamide 5 2.50 Å 5CGH 5CGH 5CGH 5CGH 5CGH 5CGH Dubiella et al., 2015
20S proteasome beta5 Gly48Cys mutant; complex with ONX 0914 2.80 Å 5CGI 5CGI 5CGI 5CGI 5CGI 5CGI Dubiella et al., 2015
yeast 20s proteasome at 2.3 a resolution 2.30 Å 5CZ4 5CZ4 5CZ4 5CZ4 5CZ4 5CZ4
yeast 20s proteasome beta1-t1a mutant in complex with carfilzomib 2.80 Å 5CZ5 5CZ5 5CZ5 5CZ5 5CZ5 5CZ5
yeast 20s proteasome beta5-t1a mutant in complex with syringolin a, propeptide expressed in trans 2.70 Å 5CZ6 5CZ6 5CZ6 5CZ6 5CZ6 5CZ6
yeast 20s proteasome beta5-t1a beta5-k81r double mutant in complex with bortezomib, propeptide expressed in cis 2.50 Å 5CZ7 5CZ7 5CZ7 5CZ7 5CZ7 5CZ7
yeast 20s proteasome beta5-l(-49)s-k33a mutant in complex with carfilzomib 2.80 Å 5CZ8 5CZ8 5CZ8 5CZ8 5CZ8 5CZ8
yeast 20s proteasome beta5-d17n mutant in complex with carfilzomib; propeptide expressed in trans 2.90 Å 5CZ9 5CZ9 5CZ9 5CZ9 5CZ9 5CZ9
yeast 20s proteasome beta5-d166n mutant 2.50 Å 5CZA 5CZA 5CZA 5CZA 5CZA 5CZA
yeast 20s proteasome beta5-d166n mutant in complex with carfilzomib 2.50 Å 5D0S 5D0S 5D0S 5D0S 5D0S 5D0S
20s proteasome beta5-Asp166Asn mutant; complex with MG132 2.60 Å 5D0T 5D0T 5D0T 5D0T 5D0T 5D0T
yeast 20s proteasome beta5-t1c mutant in complex with carfilzomib 2.90 Å 5D0V 5D0V 5D0V 5D0V 5D0V 5D0V
yeast 20s proteasome beta5-t1s mutant 2.80 Å 5D0W 5D0W 5D0W 5D0W 5D0W 5D0W
yeast 20s proteasome beta5-t1s mutant in complex with bortezomib 2.60 Å 5D0X 5D0X 5D0X 5D0X 5D0X 5D0X
yeast 20s proteasome beta5-t1s mutant in complex with carfilzomib 2.90 Å 5D0Z 5D0Z 5D0Z 5D0Z 5D0Z 5D0Z
20S proteasome; complex with alkyne-PI 2.80 Å 5DKI 5DKI 5DKI 5DKI 5DKI 5DKI
20S proteasome; complex with octreotide-PI 2.80 Å 5DKJ 5DKJ 5DKJ 5DKJ 5DKJ 5DKJ
yeast 20s proteasome beta2-t1a mutant 2.70 Å 5FG7 5FG7 5FG7 5FG7 5FG7 5FG7
yeast 20s proteasome beta2-t(-2)v mutant 2.60 Å 5FG9 5FG9 5FG9 5FG9 5FG9 5FG9
yeast 20s proteasome beta5-k33a mutant (propeptide expressed in trans) 2.70 Å 5FGA 5FGA 5FGA 5FGA 5FGA 5FGA
yeast 20s proteasome beta5-h(-2)l-t1a double mutant in complex with carfilzomib 2.80 Å 5FGD 5FGD 5FGD 5FGD 5FGD 5FGD
yeast 20s proteasome beta5-h(-2)t-t1a double mutant in complex with carfilzomib 2.60 Å 5FGE 5FGE 5FGE 5FGE 5FGE 5FGE
yeast 20s proteasome beta5-h(-2)a-t1a-k81r triple mutant in complex with carfilzomib 2.60 Å 5FGF 5FGF 5FGF 5FGF 5FGF 5FGF
yeast 20s proteasome beta5-l(-49s)_d17n double mutant in complex with carfilzomib 2.70 Å 5FGG 5FGG 5FGG 5FGG 5FGG 5FGG
20s proteasome beta5-Lys33Ala mutant (propeptide expressed in trans); complex with MG132 2.80 Å 5FGH 5FGH 5FGH 5FGH 5FGH 5FGH
yeast 20s proteasome beta1-t1a beta2-t1a double mutant in complex withcarfilzomib 2.90 Å 5FGI 5FGI 5FGI 5FGI 5FGI 5FGI
yeast 20s proteasome beta5-k33a mutant (propeptide expressed in trans)in complex with carfilzomib 2.70 Å 5FHS 5FHS 5FHS 5FHS 5FHS 5FHS
20s proteasome; complex with the peptidic epoxyketone inhibitor 27 2.90 Å 5JHR 5JHR 5JHR 5JHR 5JHR 5JHR
20s proteasome; complex with the peptidic epoxyketone inhibitor 15 3.00 Å 5JHS 5JHS 5JHS 5JHS 5JHS 5JHS
20s proteasome; complex with epoxyketone inhibitor 14 2.70 Å 5L52 5L52 5L52 5L52 5L52 5L52
20s proteasome; complex with epoxyketone inhibitor 16 2.80 Å 5L54 5L54 5L54 5L54 5L54 5L54
20s proteasome; complex with epoxyketone inhibitor 18 2.90 Å 5L55 5L55 5L55 5L55 5L55 5L55
yeast 20s proteasome with human beta5i (1-138; r57t) 2.40 Å 5L5A 5L5A 5L5A 5L5A 5L5A 5L5A
yeast 20s proteasome with human beta5i (1-138) and human beta6 (97- 111; 118-133) 2.80 Å 5L5B 5L5B 5L5B 5L5B 5L5B 5L5B
yeast 20s proteasome with human beta5i (1-138) and human beta6 (97- 111; 118-133) in complex with onx 0914 2.80 Å 5L5D 5L5D 5L5D 5L5D 5L5D 5L5D
yeast 20s proteasome with human beta5i (1-138) and human beta6 (97- 111; 118-133) in complex with carfilzomib 2.90 Å 5L5E 5L5E 5L5E 5L5E 5L5E 5L5E
yeast 20s proteasome with human beta5i (1-138) and human beta6 (97- 111; 118-133) in complex with bortezomib 2.50 Å 5L5F 5L5F 5L5F 5L5F 5L5F 5L5F
yeast 20s proteasome with human beta5i (1-138) and human beta6 (97- 111; 118-133); complex with PR-924 2.60 Å 5L5H 5L5H 5L5H 5L5H 5L5H 5L5H
yeast 20s proteasome with human beta5i (1-138) and human beta6 (97- 111; 118-133) in complex with epoxyketone inhibitor 9 2.90 Å 5L5I 5L5I 5L5I 5L5I 5L5I 5L5I
yeast 20s proteasome with human beta5i (1-138) and human beta6 (97- 111; 118-133) in complex with epoxyketone inhibitor 14 2.90 Å 5L5J 5L5J 5L5J 5L5J 5L5J 5L5J
yeast 20s proteasome with human beta5i (1-138) and human beta6 (97- 111; 118-133) in complex with epoxyketone inhibitor 16 2.60 Å 5L5O 5L5O 5L5O 5L5O 5L5O 5L5O
yeast 20s proteasome with human beta5i (1-138) and human beta6 (97- 111; 118-133) in complex with epoxyketone inhibitor 17 2.80 Å 5L5P 5L5P 5L5P 5L5P 5L5P 5L5P
yeast 20s proteasome with human beta5i (1-138) and human beta6 (97- 111; 118-133) in complex with epoxyketone 18 2.80 Å 5L5Q 5L5Q 5L5Q 5L5Q 5L5Q 5L5Q
yeast 20s proteasome with human beta5i (1-138;v31m) and human beta6 (97-111; 118-133) 2.90 Å 5L5R 5L5R 5L5R 5L5R 5L5R 5L5R
yeast 20s proteasome with human beta5i (1-138; Val31Met mutant) and human beta6 (97-111; 118-133); complex with PR-924 2.60 Å 5L5S 5L5S 5L5S 5L5S 5L5S 5L5S
yeast 20s proteasome with human beta5i (1-138; v31m) and human beta6 (97-111; 118-133) in complex with epoxyketone inhibitor 16 2.90 Å 5L5T 5L5T 5L5T 5L5T 5L5T 5L5T
yeast 20s proteasome with human beta5i (1-138; v31m) and human beta6 (97-111; 118-133) in complex with epoxyketone inhibitor 17 ***caveat 5l5u 04c h 301 has wrong chirality at atom c27 04c k 301 has ***caveat 2 5l5u wrong chirality at atom c27 04c v 301 h 2.60 Å 5L5U 5L5U 5L5U 5L5U 5L5U 5L5U
yeast 20s proteasome with human beta5c (1-138) and human beta6 (97- 111; 118-133) 2.80 Å 5L5W 5L5W 5L5W 5L5W 5L5W 5L5W
yeast 20s proteasome with human beta5c (1-138) and human beta6 (97- 111; 118-133) in complex with onx 0914 2.90 Å 5L5X 5L5X 5L5X 5L5X 5L5X 5L5X
yeast 20s proteasome with human beta5c (1-138) and human beta6 (97- 111; 118-133) in complex with carfilzomib 2.70 Å 5L5Y 5L5Y 5L5Y 5L5Y 5L5Y 5L5Y
yeast 20s proteasome with human beta5c (1-138) and human beta6 (97- 111; 118-133) in complex with bortezomib 2.70 Å 5L5Z 5L5Z 5L5Z 5L5Z 5L5Z 5L5Z
yeast 20s proteasome with human beta5c (1-138) and human beta6 (97- 111; 118-133); complex with PR-924 2.70 Å 5L60 5L60 5L60 5L60 5L60 5L60
yeast 20s proteasome with human beta5c (1-138) and human beta6 (99- 132) in complex with epoxyketone inhibitor 14 2.80 Å 5L61 5L61 5L61 5L61 5L61 5L61
yeast 20s proteasome with human beta5c (1-138) and human beta6 (97- 111; 118-133) in complex with epoxyketone inhibitor 16 2.80 Å 5L62 5L62 5L62 5L62 5L62 5L62
yeast 20s proteasome with human beta5c (1-138) and human beta6 (97- 111; 118-133) in complex with epoxyketone inhibitor 17 ***caveat 5l63 04c h 301 has wrong chirality at atom c27 04c k 301 has ***caveat 2 5l63 wrong chirality at atom c27 04c v 301 has wr 2.70 Å 5L63 5L63 5L63 5L63 5L63 5L63
yeast 20s proteasome with human beta5c (1-138) and human beta6 (97- 111; 118-133) in complex with epoxyketone inhibitor 18 2.70 Å 5L64 5L64 5L64 5L64 5L64 5L64
yeast 20s proteasome with mouse beta5i (1-138) and mouse beta6 (97- 111; 118-133) in complex with carfilzomib 2.90 Å 5L65 5L65 5L65 5L65 5L65 5L65
yeast 20s proteasome with mouse beta5i (1-138) and mouse beta6 (97- 111; 118-133) in complex with bortezomib 2.80 Å 5L66 5L66 5L66 5L66 5L66 5L66
yeast 20s proteasome with mouse beta5i (1-138) and mouse beta6 (97- 111; 118-133); complex with PR-924 2.60 Å 5L67 5L67 5L67 5L67 5L67 5L67
yeast 20s proteasome with mouse beta5i (1-138) and mouse beta6 (97- 111; 118-133) in complex with epoxyketone inhibitor 14 2.80 Å 5L68 5L68 5L68 5L68 5L68 5L68
yeast 20s proteasome with mouse beta5i (1-138) and mouse beta6 (97- 111; 118-133) in complex with epoxyketone inhibitor 16 2.70 Å 5L69 5L69 5L69 5L69 5L69 5L69
yeast 20s proteasome with mouse beta5i (1-138) and mouse beta6 (97- 111; 118-133) in complex with epoxyketone inhibitor 17 2.80 Å 5L6A 5L6A 5L6A 5L6A 5L6A 5L6A
yeast 20s proteasome with mouse beta5i (1-138) and mouse beta6 (97- 111; 118-133) in complex with onx 0914 2.60 Å 5L6B 5L6B 5L6B 5L6B 5L6B 5L6B
yeast 20s proteasome with mouse beta5i (1-138) and mouse beta6 (97- 111; 118-133) in complex with epoxyketone inhibitor 18 2.60 Å 5L6C 5L6C 5L6C 5L6C 5L6C 5L6C
ligand-induced aziridine-formation at the yeast proteasomal subunit beta5 by sulfonate esters 2.50 Å 5LAI 5LAI 5LAI 5LAI 5LAI 5LAI
ligand-induced lys33-thr1 crosslinking at the yeast proteasomal subunit beta5 by sulfonate esters 2.90 Å 5LAJ 5LAJ 5LAJ 5LAJ 5LAJ 5LAJ
yeast 20s proteasome with human beta5i (1-138; Arg57Thr mutant)in complex with PR-924 2.70 Å 5LTT 5LTT 5LTT 5LTT 5LTT 5LTT
yeast 20s proteasome with human beta5i (1-138) and human beta6 (97- 111; 118-133) in complex with thiazole based inhibitor ro19 2.70 Å 5M2B 5M2B 5M2B 5M2B 5M2B 5M2B
26s proteasome in presence of atp (s1) 4.10 Å 5MP9 5MP9 5MP9 5MP9 5MP9 5MP9
26s proteasome in presence of atp (s2) 4.50 Å 5MPA 5MPA 5MPA 5MPA 5MPA 5MPA
yeast 20s proteasome in complex with blm-pep activator 3.00 Å 5NIF 5NIF 5NIF 5NIF 5NIF 5NIF
yeast 26s proteasome bound to ubiquitinated substrate (4d motor state) 4.17 Å 6EF3 6EF3 6EF3 6EF3 6EF3 6EF3
yeast 20s proteasome in complex with cystargolide B 2.70 Å 6G7F 6G7F 6G7F 6G7F 6G7F 6G7F
yeast 20s proteasome in complex with cystargolide B derivative 1 2.70 Å 6G8M 6G8M 6G8M 6G8M 6G8M 6G8M
yeast 20s proteasome in complex with cystargolide B derivative 2 3.00 Å 6G8N 6G8N 6G8N 6G8N 6G8N 6G8N
yeast 20s proteasome in complex with homosalinosporamide a 2.90 Å 6GOP 6GOP 6GOP 6GOP 6GOP 6GOP
yeast 20s proteasome in complex with the peptidic non-covalent bindinginhibitor rts-v5 2.50 Å 6H39 6H39 6H39 6H39 6H39 6H39
yeast 20s proteasome with human beta2c (s171g) 2.70 Å 6HTB 6HTB 6HTB 6HTB 6HTB 6HTB
yeast 20s proteasome with human beta2c (s171g) in complex with onx 0914 2.80 Å 6HTC 6HTC 6HTC 6HTC 6HTC 6HTC
yeast 20s proteasome with human beta2c (s171g) in complex with 4 3.00 Å 6HTD 6HTD 6HTD 6HTD 6HTD 6HTD
yeast 20s proteasome with human beta2c (s171g) in complex with 7 3.00 Å 6HTP 6HTP 6HTP 6HTP 6HTP 6HTP
yeast 20s proteasome with human beta2c (s171g) in complex with 13 2.60 Å 6HTR 6HTR 6HTR 6HTR 6HTR 6HTR
yeast 20s proteasome with human beta2c (s171g) in complex with 16 2.90 Å 6HUB 6HUB 6HUB 6HUB 6HUB 6HUB
yeast 20s proteasome with human beta2c (s171g) in complex with 18 3.00 Å 6HUC 6HUC 6HUC 6HUC 6HUC 6HUC
yeast 20s proteasome with human beta2c (s171g) in complex with 20 3.00 Å 6HUQ 6HUQ 6HUQ 6HUQ 6HUQ 6HUQ
yeast 20s proteasome with human beta2c (s171g) in complex with 29 2.80 Å 6HUU 6HUU 6HUU 6HUU 6HUU 6HUU
yeast 20s proteasome with human beta2c (s171g) in complex with 39 3.10 Å 6HUV 6HUV 6HUV 6HUV 6HUV 6HUV
yeast 20s proteasome with human beta2i (1-53) 2.70 Å 6HV3 6HV3 6HV3 6HV3 6HV3 6HV3
yeast 20s proteasome with human beta2i (1-53) in complex with onx 0914 3.00 Å 6HV4 6HV4 6HV4 6HV4 6HV4 6HV4
yeast 20s proteasome with human beta2i (1-53) in complex with 4 3.00 Å 6HV5 6HV5 6HV5 6HV5 6HV5 6HV5
yeast 20s proteasome with human beta2i (1-53) in complex with 7 3.40 Å 6HV7 6HV7 6HV7 6HV7 6HV7 6HV7
yeast 20s proteasome with human beta2i (1-53) in complex with 13 2.90 Å 6HVA 6HVA 6HVA 6HVA 6HVA 6HVA
yeast 20s proteasome with human beta2i (1-53) in complex with 16 2.70 Å 6HVR 6HVR 6HVR 6HVR 6HVR 6HVR
yeast 20s proteasome with human beta2i (1-53) in complex with 18 3.10 Å 6HVS 6HVS 6HVS 6HVS 6HVS 6HVS
yeast 20s proteasome with human beta2i (1-53) in complex with 20 2.90 Å 6HVT 6HVT 6HVT 6HVT 6HVT 6HVT
yeast 20s proteasome with human beta2i (1-53) in complex with 29 2.90 Å 6HVU 6HVU 6HVU 6HVU 6HVU 6HVU
yeast 20s proteasome with human beta2i (1-53) in complex with 39 2.70 Å 6HVV 6HVV 6HVV 6HVV 6HVV 6HVV
yeast 20s proteasome with human beta2i (1-53) in complex with 43 3.00 Å 6HVW 6HVW 6HVW 6HVW 6HVW 6HVW
yeast 20s proteasome in complex with 4 2.80 Å 6HVX 6HVX 6HVX 6HVX 6HVX 6HVX
yeast 20s proteasome in complex with 5 (7- and 6-membered ring) 2.70 Å 6HVY 6HVY 6HVY 6HVY 6HVY 6HVY
yeast 20s proteasome in complex with 7 2.80 Å 6HW0 6HW0 6HW0 6HW0 6HW0 6HW0
yeast 20s proteasome in complex with 13 2.60 Å 6HW3 6HW3 6HW3 6HW3 6HW3 6HW3
yeast 20s proteasome in complex with 16 2.90 Å 6HW4 6HW4 6HW4 6HW4 6HW4 6HW4
yeast 20s proteasome in complex with 18 2.90 Å 6HW5 6HW5 6HW5 6HW5 6HW5 6HW5
yeast 20s proteasome in complex with 20 2.70 Å 6HW6 6HW6 6HW6 6HW6 6HW6 6HW6
yeast 20s proteasome in complex with 29 2.70 Å 6HW7 6HW7 6HW7 6HW7 6HW7 6HW7
yeast 20s proteasome in complex with 39 2.80 Å 6HW8 6HW8 6HW8 6HW8 6HW8 6HW8
yeast 20s proteasome in complex with 41b 2.80 Å 6HW9 6HW9 6HW9 6HW9 6HW9 6HW9
yeast 20s proteasome in complex with 43 2.80 Å 6HWA 6HWA 6HWA 6HWA 6HWA 6HWA
yeast 20s proteasome in complex with 44b 2.60 Å 6HWB 6HWB 6HWB 6HWB 6HWB 6HWB
yeast 20s proteasome beta2-g45a mutant 2.80 Å 6HWC 6HWC 6HWC 6HWC 6HWC 6HWC
yeast 20s proteasome beta2-g45a mutant in complex with bortezomib 2.80 Å 6HWD 6HWD 6HWD 6HWD 6HWD 6HWD
yeast 20s proteasome beta2-g45a mutant in complex with carfilzomib 2.30 Å 6HWE 6HWE 6HWE 6HWE 6HWE 6HWE
yeast 20s proteasome beta2-g45a mutant in complex with onx 0914 2.50 Å 6HWF 6HWF 6HWF 6HWF 6HWF 6HWF

feedback
Page created 8-September-2023

EMBL-EBI logo

© 2023 EBI
Terms of use